NRX Pharmaceuticals, Inc. - $NRXP STOCK NEWS

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will report its first quarter 2024 financial results on May 14, 2024. The Company, a clinical-stage biopharmaceutical firm, will share the results via a press release and host a conference call to discuss them and provide a corporate update.

NRx Pharmaceuticals (NRXP) has announced final clinical trial results showing a superior safety profile of NRX-101 compared to Lurasidone in treating suicidal bipolar depression. NRX-101 demonstrated a 76% reduction in akathisia symptoms with essentially zero levels at day 42, while also seeking accelerated FDA approval for use in patients at risk of akathisia. The study will be presented at the ASCP meeting in May 2024.

NRx Pharmaceuticals (NRXP) announced promising findings in a Phase 2b/3 clinical trial of NRX-101 vs. Lurasidone for the treatment of suicidal bipolar depression. NRX-101 demonstrated a 33% advantage in sustained remission in suicidality and a 75% advantage in relief from Akathisia compared to Lurasidone. Data from the study support an approval pathway for NRX-101 to become a standard of care in the treatment of bipolar depression. The trial showed comparable results to previous trials and expanded the potential utility of NRx-101 for a larger patient population. The company aims to change the treatment paradigm for patients with a high suicide risk, providing a potential blockbuster drug.

NRx Pharmaceuticals (NASDAQ:NRXP) has received confirmation from Nasdaq that they have demonstrated compliance with the bid price requirement, ensuring the continued listing of the Company's securities. The Company is now focused on achieving four key milestones, including releasing data from trials in Suicidal Bipolar Depression and Chronic Pain, filing an NDA for IV Ketamine, and distributing shares of HOPE Therapeutics to existing shareholders. Recent unexpected achievements related to intravenous ketamine and complicated Urinary Tract Infection/pyelonephritis show promising potential for shareholder value.

NRx Pharmaceuticals, Inc. announced the pricing of a $2.0 million underwritten public offering of common stock at $3.30 per share. The company granted the underwriters an option to purchase additional shares. The offering is expected to close on April 19, 2024. NRx Pharmaceuticals plans to use the proceeds for working capital, general corporate purposes, and debt repayment.

NRx Pharmaceuticals, Inc. announces a proposed underwritten public offering of common stock to raise funds for working capital, general corporate purposes, and debt repayment. The offering is subject to market conditions, with EF Hutton as the sole book-running manager. The net proceeds will be used for a national treatment protocol and safety database.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced new data on NRX-101 showing no damage to intestinal and vaginal flora in rodent models, potentially avoiding C. difficile infections. NRX-101 has FDA QIDP and Fast Track Designation for cUTI and Pyelonephritis.

NRx Pharmaceuticals (NASDAQ:NRXP) announced the development of a new, proprietary formulation of IV Ketamine, HTX-100. The formulation achieves a pH-neutral state, enabling both intravenous and subcutaneous administration. The company expects patent protection and has partnered with Nephron Pharmaceuticals to generate patents. HTX-100 is set to be marketed by HOPE Therapeutics, a subsidiary of NRx.

NRx Pharmaceuticals achieves data-lock in Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101, anticipates top-line data release in April 2024. Positive results lead to additional milestone payments and future development costs covered by partners. NRX-101 demonstrates potential for a broader patient population, with FDA designations and successful trials positioning it as a promising therapy for suicidal bipolar depression.